“Up to 25 percent of the human genome is critical, while the rest has no function, according to a study published July 11 in Genome Biology and Evolution. The estimate, generated by looking at fertility rates and the expected frequency of deleterious mutations, contradicts a 2012 claim from a large international group called ENCODE, which estimated that 80 percent of the genome is functional.”
Integrating Genomics into Public Health Surveillance: Ushering in a New Era of Precision Public Health
by Muin J Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention Continue reading
“Application of the experimental design of genome-wide association studies (GWASs) is now 10 years old (young), and here we review the remarkable range of discoveries it has facilitated in population and complex-trait genetics, the biology of diseases, and translation toward new therapeutics. We predict the likely discoveries in the next 10 years, when GWASs will be based on millions of samples with array data imputed to a large fully sequenced reference panel and on hundreds of thousands of samples with whole-genome sequencing data…
“The Internet is under attack, and not just by hackers, thieves and spies. As Alexander Klimburg reports in The Darkening Web, governments that insist on their own primacy are increasingly assaulting the idea of this digitized landscape as a transnational commons. Cyberspace is becoming a war zone in a new era of ideological combat..’
An interesting study was published yesterday in Current Biology about the the history of modern horses.
In order to investigate this history, Barbara Wallner and her colleagues at the University of Veterinary Medicine Vienna used next-generation sequencing of the Y chromosomes of 52 stallions from 21 breeds.
By Seraya Maouche | May 5, 2017
Lancée en 2013, « Reproducibility Project » est une initiative de science ouverte pour reproduire les résultats de a recherche biomédicale. Le projet a publié, en début de cette année, ses premiers résultats qui pourraient faire mal aux ambitions de certaines sociétés biotechnologiques dont une phase de levée de fonds est nécessaire pour financer le développement de nouveaux médicaments. Continue reading